BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38808744)

  • 21. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.
    Major A; Kamdar M
    Curr Treat Options Oncol; 2018 May; 19(7):33. PubMed ID: 29797086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-transplant lymphoproliferative disorder.
    Kalinova L; Indrakova J; Bachleda P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Dec; 153(4):251-7. PubMed ID: 20208963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation.
    Green M
    Am J Transplant; 2001 Jul; 1(2):103-8. PubMed ID: 12099356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.
    Green M; Michaels MG; Webber SA; Rowe D; Reyes J
    Pediatr Transplant; 1999 Nov; 3(4):271-81. PubMed ID: 10562971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.
    Wistinghausen B; Gross TG; Bollard C
    Pediatr Hematol Oncol; 2013 Sep; 30(6):520-31. PubMed ID: 23802715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B; Riella LV; Dierickx D
    Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transplant lymphoproliferative disorders following solid-organ transplantation.
    Blaes AH; Morrison VA
    Expert Rev Hematol; 2010 Feb; 3(1):35-44. PubMed ID: 21082932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
    Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL; Marcus R; Bradley JA
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
    Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
    Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience.
    Nakanishi C; Kawagishi N; Sekiguchi S; Akamatsu Y; Sato K; Miyagi S; Takeda I; Fukushima D; Kobayashi Y; Ishida K; Niizuma H; Tsuchiya S; Wada M; Nio M; Satomi S
    Surg Today; 2012 Aug; 42(8):741-51. PubMed ID: 22278621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-transplant lymphoproliferative disease in children, adolescents, and young adults.
    Gross TG; Rubinstein JD
    Hematol Oncol; 2023 Jun; 41 Suppl 1():48-56. PubMed ID: 37294957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder.
    Green M; Michaels MG
    Am J Transplant; 2013 Feb; 13 Suppl 3():41-54; quiz 54. PubMed ID: 23347213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series.
    Montanari F; Radeski D; Seshan V; Alobeid B; Bhagat G; O'Connor OA
    Br J Haematol; 2015 Nov; 171(4):491-500. PubMed ID: 26250758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience.
    Bosse RC; Franke AJ; Paul Skelton W; Woody LE; Bishnoi R; Wang Y; Bhaduri-McIntosh S; Rajderkar D; Shih R; Dang NH; Slayton WB
    Pediatr Transplant; 2020 Aug; 24(5):e13747. PubMed ID: 32497335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of post-transplant lymphoproliferative disorders.
    DeStefano CB; Desai SH; Shenoy AG; Catlett JP
    Br J Haematol; 2018 Aug; 182(3):330-343. PubMed ID: 29741774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.